The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve...

Full description

Bibliographic Details
Main Authors: Francisco Quiñonero, Cristina Mesas, Kevin Doello, Laura Cabeza, Gloria Perazzoli, Cristina Jimenez-Luna, Ana Rosa Rama, Consolación Melguizo, Jose Prados
Format: Article
Language:English
Published: China Anti-Cancer Association 2019-12-01
Series:Cancer Biology & Medicine
Subjects:
pancreatic ductal adenocarcinoma
chemotherapy
drug resistance
cancer stem cells
therapeutic strategies
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1516

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1516

Similar Items